IDT Australia (ASX:IDT) 3-Year EBITDA Growth Rate: -146.60% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is IDT Australia 3-Year EBITDA Growth Rate?

IDT Australia ASX:IDT +11.63% 3-Year EBITDA Growth Rate is -146.60% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 811 Drug Manufacturers companies, IDT Australia ranks worse than 99.51% on this metric.

IDT Australia's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was -146.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of IDT Australia was 74.50% per year. The lowest was -146.60% per year. And the median was 9.60% per year.

IDT Australia  (ASX:IDT) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

IDT Australia 3-Year EBITDA Growth Rate Related Terms

ASX:IDT vs ZTS: 3-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDT Australia 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, IDT Australia's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where IDT Australia's 3-Year EBITDA Growth Rate falls into.


IDT Australia 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of -146.60% mean?
IDT Australia (ASX:IDT) has a 3-Year EBITDA Growth Rate of -146.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IDT Australia and its competitors. According to the industry distribution chart, IDT Australia ranks #807 out of 811 companies in the Drug Manufacturers industry, placing it in the top 99.5%.
Is IDT Australia's 3-Year EBITDA Growth Rate too high?
IDT Australia's current 3-Year EBITDA Growth Rate is -146.60%. Based on the distribution chart, IDT Australia ranks #807 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does IDT Australia's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, IDT Australia ranks #807 out of 811 companies for 3-Year EBITDA Growth Rate. This places IDT Australia in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IDT Australia and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDT Australia's current 3-Year EBITDA Growth Rate is -146.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDT Australia stock overvalued right now?
Based on GuruFocus' analysis, IDT Australia (ASX:IDT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.17, compared to a current price of A$0.05 — trading 71.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -146.60%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For IDT Australia (ASX:IDT), the current 3-Year EBITDA Growth Rate is -146.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IDT Australia Business Description

Address 45 Wadhurst Drive, Boronia, Melbourne, VIC, AUS, 3155
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services. The company operates in Australia, Asia, Europe, and the USA.